

DAVID Y. IGE GOVERNOR

July 12, 2022

EXECUTIVE CHAMBERS

The Honorable Ronald D. Kouchi,
President
and Members of the Senate
Thirty-First State Legislature
State Capitol, Room 409
Honolulu, Hawai'i 96813

The Honorable Scott K. Saiki, Speaker and Members of the House of Representatives Thirty-First State Legislature State Capitol, Room 431 Honolulu, Hawai'i 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

I am transmitting herewith SB2032 SD2 HD2 CD1, without my approval and with the statement of objections relating to the measure.

SB2032 SD2 HD2 CD1

RELATING TO GENETIC INFORMATION PRIVACY.

Sincerely,

DAVID Y. IGE

Governor, State of Hawai'i

EXECUTIVE CHAMBERS HONOLULU July 12, 2022

STATEMENT OF OBJECTIONS TO SENATE BILL NO. 2032

Honorable Members Thirty-First Legislature State of Hawai'i

Pursuant to Section 16 of Article III of the Constitution of the State of Hawai'i, I am returning herewith, without my approval, Senate Bill No. 2032, entitled "A Bill for an Act Relating to Genetic Information Privacy."

The purpose of this bill is to regulate direct-to-consumer genetic testing products to protect the privacy and confidentiality of consumers' genetic data. This bill requires direct-to-consumer genetic testing companies to adhere to certain requirements pertaining to the collection, use, and disclosure of genetic data.

This bill is objectionable because while the bill's purpose to protect the consumers' privacy and confidentiality is admirable, the enforcement mechanism provided in the bill appears to be problematic. Specifically, the bill requires the Office of Consumer Protection (OCP) to bring actions to enforce violations through the Attorney General, thereby depriving OCP of its independent authority under section 487-5, Hawaii Revised Statutes (HRS), to initiate actions for the violation of laws enacted for the purpose of consumer protection. In addition, it is not clear whether a consumer would retain the right to file a claim for an unfair and deceptive trade practice under chapter 480, HRS, for a violation of the prohibitions or requirements set forth in the bill. The lack of clarity may inadvertently and undesirably deter consumers from filing their own claims against direct-to-consumer genetic testing companies under chapter 480, HRS.

STATEMENT OF OBJECTIONS SENATE BILL NO. 2032 Page 2

For the foregoing reasons, I am returning Senate Bill No. 2032 without my approval.

Respectfully,

DAVID Y. IGE

Governor of Hawai'i

VETO

THE SENATE THIRTY-FIRST LEGISLATURE, 2022 STATE OF HAWAII S.B. NO. 2032 S.D. 2 H.D. 2 C.D. 1

A BILL FOR AN ACT

RELATING TO GENETIC INFORMATION PRIVACY.

	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
1	SECTION 1. The legislature finds that the number of
2	companies offering direct-to-consumer genetic tests, otherwise
3	known as ancestry tests, at-home genetic tests, direct-access
4	genetic tests, genealogy tests, and home deoxyribonucleic acid
5	(DNA) tests, has been growing, along with the range of
6	information on the health conditions and traits covered by the
7	tests.
8	Direct-to-consumer genetic tests provide consumers with
9	direct access to their genetic information without the
10	involvement of health care providers and health plans. As the
11	name suggests, the tests are marketed directly to consumers
12	through the media, print advertisements, or the Internet, and
13	purchased by consumers online or in stores. The consumers
14	collect and mail their DNA samples pursuant to instructions
15	provided by the direct-to-consumer genetic testing company, and
16	a laboratory analyzes the DNA samples for genetic variations

18 results are communicated to the consumer varies by company; some 2022-3172 SB2032 CD1 SMA.doc

that fit the purpose of the test. The method by which the test

17

- 1 post the results on a secure website that the consumer can
- 2 access, some mail a written report to the consumer, and some
- 3 share the results over the telephone.
- 4 While direct-to-consumer genetic testing promotes awareness
- 5 of genetic diseases and can assist consumers in taking a
- 6 proactive role in maintaining or improving their health and
- 7 wellness, the legislature is concerned that there is currently
- 8 little oversight or regulation of direct-to-consumer genetic
- 9 testing companies, especially in terms of how the privacy and
- 10 confidentiality of a consumer's genetic information are
- 11 protected. The legislature acknowledges that the Health
- 12 Insurance Portability and Accountability Act of 1996 (HIPAA)
- 13 established national standards to protect an individual's
- 14 medical records and other personal health information, including
- 15 genetic information. However, HIPAA applies only to health
- 16 plans, health care clearinghouses, and certain health care
- 17 providers; it does not apply to direct-to-consumer genetic
- 18 testing companies.
- 19 Accordingly, the purpose of this Act is to protect the
- 20 privacy and confidentiality of genetic data of consumers who
- 21 order or purchase a genetic testing product or service and

- 1 submit their biological samples to direct-to-consumer genetic
- 2 testing companies by requiring direct-to-consumer genetic
- 3 testing companies to adhere to certain requirements pertaining
- 4 to the collection, use, and disclosure of genetic data.
- 5 SECTION 2. The Hawaii Revised Statutes is amended by
- 6 adding a new chapter to be appropriately designated and to read
- 7 as follows:
- 8 "CHAPTER
- 9 HAWAII GENETIC INFORMATION PRIVACY ACT
- 10 § -1 Short title. This chapter shall be known and may
- 11 be cited as the Hawaii Genetic Information Privacy Act.
- 12 § -2 Definitions. As used in this chapter, unless the
- 13 context clearly requires otherwise:
- "Biological sample" means any material part of a human
- 15 being, discharge from a human being, or derivative of a human
- 16 being that is known to contain the DNA of the human being.
- 17 "Biological sample" includes the tissue, blood, urine, and
- 18 saliva of a human being.
- 19 "Consumer" means any individual who is a resident of the
- 20 State.

S.B. NO. S.D. 2032 S.D. 2032 H.D. 2

1	"De-identified data" means data that has been de-identified
2	in accordance with title 45 Code of Federal Regulations
3	section 164.514(b).
4	"Direct-to-consumer genetic testing company" or "company"
5	means any person that provides direct-to-consumer genetic
6	testing products or services related to direct-to-consumer
7	genetic testing products directly to consumers. For purposes of
8	this definition, services related to direct-to-consumer genetic
9	testing products include:
10	(1) Collecting or receiving biological samples or genetic
11	data from a consumer;
12	(2) Analyzing the genetic data derived from the biological
13	samples or genetic data of a consumer; and
14	(3) Communicating the results of the genetic testing to
15	the consumer.
16	"Direct-to-consumer genetic testing company" does not include
17	any covered entity as defined under title 45 Code of Federal
18	Regulations section 160.103, established pursuant to the Health
19	Insurance Portability and Accountability Act of 1996.
20	"Direct-to-consumer genetic testing product" means genetic
21	tests that are marketed directly to consumers and nurchased by

S.B. NO. S.D. 2 S.D. 2 H.D. 2 C.D. 1

1	the consumer	r online or in stores. "Direct-to-consumer genetic
2	testing prod	duct" includes ancestry tests, at-home genetic tests,
3	direct-acces	ss genetic tests, genealogy tests, and home DNA
4	tests.	
5	"DNA" (means deoxyribonucleic acid.
6	"Genet:	ic data" means data in any format that contain
7	information	relating to a consumer's genetic characteristics.
8	"Genetic dat	ta" includes:
9	(1) Ra	aw sequence data that result from the sequencing of a
10	Co	onsumer's complete extracted DNA or a portion of the
11	e	xtracted DNA;
12	(2) G	enotypic and phenotypic information that results from
13	aı	nalyzing the raw sequence data; and
14	(3) S	elf-reported health information regarding a
15	C	onsumer's health conditions that the consumer submits
16	t	o a direct-to-consumer genetic testing company that
17	i	s:
18	()	A) Analyzed in connection with the consumer's raw
19		sequence data; or
20	(1	B) Used for scientific research or product
21		development.

S.B. NO. S.D. 2 H.D. 2 C.D. 1

1	"Genetic data" does not include de-identified data.
2	"Genetic test" or "genetic testing" means any laboratory
3	test of a consumer's complete DNA, regions of DNA, chromosomes,
4	genes, or gene products to determine the presence of a
5	consumer's genetic characteristics.
6	"Individual" means a natural person.
7	"Person" means any individual, group, partnership, firm,
8	association, corporation, trust, business trust, estate,
9	cooperative, consortium, joint venture, or any other form of
10	business or legal entity, and the legal representative of the
11	entity.
12	§ -3 Direct-to-consumer genetic testing company;
13	requirements; prohibition. (a) A direct-to-consumer genetic
14	testing company shall:
15	(1) Provide consumers with a clear and complete written
16	notice regarding the company's policies and procedures
17	for the collection, use, and disclosure of genetic
18	data by making available to the consumer the
19	following:
20	(A) A high-level privacy policy overview that
21	includes basic essential information about the

1			company's collection, use, and disclosure of
2			genetic data; and
3		(B)	A prominent, publicly available written privacy
4			notice that describes the company's practice
5			relating to biological samples and genetic data,
6			including genetic data collection, consumer
7			consent, use of genetic data, access to genetic
8			data, disclosure of genetic data, transfer of
9			genetic data, security protocols, and retention
10			and deletion of genetic data;
11	(2)	Obta	ain the consumer's consent for the collection, use
12		or d	disclosure of the consumer's genetic data,
13		incl	Luding:
14		(A)	Initial express consent that:
15			(i) Clearly describes how the company will use
16			the consumer's genetic data collected
17			through the direct-to-consumer genetic
18			testing product or service;
19			(ii) Specifies who has access to the consumer's
20			genetic test results; and

S.B. NO. S.D. 2 H.D. 2 C.D. 1

1	(111) Specifies now the genetic data may be
2	shared;
3	(B) Separate express consent for each of the
4	following:
5	(i) Transfer or disclosure of the consumer's
6	genetic data to any person other than the
7	company's vendors and service providers;
8	(ii) Use of the consumer's genetic data beyond
9	the primary purpose of the direct-to-
10	consumer genetic testing product or service
11	and inherent contextual uses; and
12	(iii) Retention of any biological sample provided
13	by the consumer following completion of the
14	initial genetic testing service requested b
15	the consumer;
16	(C) Informed consent in compliance with the federal
17	policy for the protection of human research
18	subjects prescribed by title 45 Code of Federal
19	Regulations part 46, for the transfer or
20	disclosure of the consumer's genetic data to
21	third-party persons for research purposes or

1		research conducted under the control of the
2		company for the purpose of publication or
3		generalizable knowledge; and
4	(1	D) Express consent for the consumer to receive
5		marketing of products and services:
6		(i) Based on the consumer's genetic data; or
7		(ii) By a third-party person based on the
8		consumer having ordered or purchased a
9		direct-to-consumer genetic testing product
10		or service.
11		For the purposes of this subparagraph,
12		"marketing" does not include the provision of
13		customized content or offers on websites or
14		through applications or services provided by the
15		direct-to-consumer genetic testing company that
16		has a first-party relationship with the consumer;
17	(3) N	ot disclose a consumer's genetic data to law
18	е	nforcement or any other government agency except when
19	r	equired under court order or pursuant to subpoena
20	i	ssued by the department of the attorney general, or
21	W	ith the prior express consent of the consumer;

S.B. NO. S.D. 2 S.D. 2 H.D. 2

1	(4)	Develop, implement, and maintain a comprehensive
2		security program to protect a consumer's genetic data
3		against unauthorized access, use, or disclosure; and
4	(5)	Provide a process that allows a consumer to:
5		(A) Access the consumer's genetic data;
6		(B) Delete the consumer's account and genetic data;
7		and
8		(C) Request and obtain the destruction of the
9		consumer's biological sample.
10	(b)	Notwithstanding any other provision in this section to
11	the contr	eary, a direct-to-consumer genetic testing company shall
12	not discl	ose a consumer's genetic data to any person offering
13	health in	surance, life insurance, or long-term care insurance,
14	or to any	employer of the consumer without the prior express
15	consent c	of the consumer.
16	(c)	Notwithstanding any other provision in this section to
17	the contr	cary, the disclosure of a consumer's genetic data
18	pursuant	to this chapter shall comply with all state and federal
19	laws gove	erning the protection of privacy and security of
20	personal	information and health information.
21	(d)	As used in this section:

1	DIS	close of disclosure means to release, transfer, or
2	otherwise	divulge a consumer's genetic data to any person other
3	than the	consumer who ordered the genetic testing.
4	"Exp	ress consent" means a statement of permission given by
5	a consume	r that is positive, direct, and unequivocal, requiring
6	no infere	nce or implication to supply its meaning, regarding the
7	collectio	n, use, or disclosure of genetic data for a specific
8	purpose.	
9	\$	-4 Exceptions. This chapter shall not apply to:
10	(1)	Protected health information that is collected by a
11		covered entity or business associate governed by the
12		privacy, security, and breach notification rules
13		issued by the United States Department of Health and
14		Human Services under title 45 Code of Federal
15		Regulations parts 160 and 164;
16	(2)	Biological samples that are obtained or genetic data
17		that is generated for the purposes of an individual's
18		medical screening, treatment, or diagnosis; and
19	(3)	A public or private institution of higher education or
20		an entity owned or operated by a public or private
21		institution of higher education

1	S	-5 Violations; civil penalties. Any person who
2	violates a	any provision of this chapter shall be assessed a civil
3	penalty of	f not less than \$2,500 for each violation in addition
4	to any ot	her applicable penalties.
5	S	-6 Enforcement; civil action; damages; costs;
6	attorneys	fees. (a) The director of the office of consumer
7	protection	n shall have concurrent jurisdiction with the attorney
8	general to	o enforce the provisions of this chapter.
9	(b)	The director of the office of consumer protection, by
10	and throu	gh the attorney general, may bring an action in any
11	court of	competent jurisdiction on behalf of the State or as
12	parens pa	triae on behalf of consumers to:
13	(1)	Enjoin any violation of this chapter;
14	(2)	Enjoin any person from continuing to engage in acts in
15		violation of this chapter or acts in furtherance
16		thereof;
17	(3)	Collect the penalties provided by section -5; or
18	(4)	Recover any damages sustained by any person injured by
19		a violation of this chapter, on whose behalf the

action was brought.

20

- 1 In any such action, the State shall also be entitled to
- 2 recover the costs of suit together with reasonable attorneys!
- 3 fees."
- 4 SECTION 3. This Act does not affect rights and duties that
- 5 matured, penalties that were incurred, and proceedings that were
- 6 begun before its effective date.
- 7 SECTION 4. If any provision of this Act, or the
- 8 application thereof to any person or circumstance, is held
- 9 invalid, the invalidity does not affect other provisions or
- 10 applications of the Act that can be given effect without the
- 11 invalid provision or application, and to this end the provisions
- 12 of this Act are severable.
- SECTION 5. This Act shall take effect upon its approval.

APPROVED this day of , 2022

GOVERNOR OF THE STATE OF HAWAII

THE SENATE OF THE STATE OF HAWAI'I

Date: May 3, 2022 Honolulu, Hawaii 96813

We hereby certify that the foregoing Bill this day passed Final Reading in the Senate of the Thirty-First Legislature of the State of Hawai'i, Regular Session of 2022.

President of the Senate

Clerk of the Senate

SB No. 2032, SD 2, HD 2, CD 1

THE HOUSE OF REPRESENTATIVES OF THE STATE OF HAWAII

Date: May 3, 2022 Honolulu, Hawaii

We hereby certify that the above-referenced Bill on this day passed Final Reading in the House of Representatives of the Thirty-First Legislature of the State of Hawaii, Regular Session of 2022.

Ban

Scott K. Saiki Speaker House of Representatives

K. L. I Rott

Brian L. Takeshita

Chief Clerk

House of Representatives